Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
GD2-CART01
i
Other names:
GD2-CART01, iC9-GD2-CAR T cells
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Bambino Gesu Hospital
Drug class:
GD2-targeted CAR-T immunotherapy
Related drugs:
‹
AUTO6NG (0)
GD2 CAR T (0)
GD2, PSMA and CD276 CAR-T (0)
GD2-CART (0)
GD2-targeted CAR-T cells (0)
iC9.GD2.CAR.IL-15 T-cells (0)
multi-CAR-T cell therapy (0)
AUTO6NG (0)
GD2 CAR T (0)
GD2, PSMA and CD276 CAR-T (0)
GD2-CART (0)
GD2-targeted CAR-T cells (0)
iC9.GD2.CAR.IL-15 T-cells (0)
multi-CAR-T cell therapy (0)
›
Associations
News
Trials
Filter by
Latest
10ms
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk And/or Relapsed/refractory Neuroblastoma or Other GD2-positive Solid Tumors (clinicaltrials.gov)
P1/2, N=42, Active, not recruiting, Bambino Gesù Hospital and Research Institute | Trial primary completion date: Dec 2024 --> Dec 2026 | Recruiting --> Active, not recruiting
10 months ago
Enrollment closed • Trial primary completion date
|
GD2-CART01
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.